The health implications of prolonged low dose radiation exposure are frequently a topic of discussion amongst vascular interventionalists, who are performing a growing number of fluoroscopically guided procedures of increasing complexity. Anecdotal evidence points to an alarming pattern of premature, atypical malignancies in high volume operators. However, in the absence of large, prospective registries relating radiation dose to long-term health effects, a causal link with prolonged exposure cannot be established.
“There is little experience with the use of cryoablation in children. Our aim was to evaluate the feasibility of cryoablation for benign soft tissue lesions in children,” said Alex M Barnacle, Great Ormond Street Hospital For Children, London, UK, speaking at the British Society of Interventional Radiology meeting (BSIR; 1–3 November, Birmingham, UK).
Mercator MedSystems has announced completion of enrolment in the company’s LIMBO-ATX (Lower-limb adventitial infusion of dexamethasone via Bullfrog to reduce occurrence of restenosis after atherectomy-based revascularisation) clinical trial. The primary six-month endpoint data is expected to be available in the second quarter of 2018.
The European Commission, under the EU Merger Regulation, has approved the acquisition of Bard by BD, subject to conditions. Both US-based companies supply medical devices including catheters, stents, surgical instruments, devices for biopsies, and patient monitoring systems.
The primary importance of collecting data from registries would be to establish outcome data to prove the value of the interventional oncologic therapies to healthcare administrations and governments; ie. to establish interventional oncology’s value in healthcare. Further, it could help gather data to confirm that interventional oncology treatments of cancer impact patients’ lives and the quality of their survival.
The US Food and Drug Administration has cleared the first seven tesla (7T) magnetic resonance imaging (MRI) device, more than doubling the static magnetic field strength available for use in the USA. The Magnetom Terra (from Siemens) is the first 7T MRI system cleared for clinical use in the USA.
Vivasure Medical has announced the successful enrolment of the first patient in the Frontier IV clinical study, a non-randomised multicentre international trial, designed to expand the indications of its proprietary PerQseal large arteriotomy closure technology. The patient was enrolled by Peter Crean (Blackrock Clinic, Dublin, Ireland).
Six-month results from a prospective, randomised, non-inferiority study presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE; 16–20 September, Copenhagen, Denmark) reveal that prostatic artery embolization is safe and effective in the treatment of benign prostatic hyperplasia (BPH) and that it results in symptomatic improvement for patients based on achieving a decrease in prostate volume.
Gerard Goh, Radiology, The Alfred Hospital, Melbourne, Australia, reported results from a comparative study of inferior vena cava (IVC) filters at CIRSE 2017 that examined the effectiveness, safety and complication rates of the Celect, Celect Platinum and ALN vena cava filters.
Scientists have discovered new information about a molecule which is part of the body’s tissue repair system. This finding could help treat non-healing wounds and injuries, such as diabetic foot.
The first patient was treated in the CONTROL hypertension (HTN)-2 clinical study, the Rox Medical’s pivotal study to evaluate the safety and effectiveness of the Rox Coupler used to create an arteriovenous anastomosis in the iliac vessels, in patients with high blood pressure.
PQ Bypass has received conditional approval of its investigational device exemption (IDE) from the US Food and Drug Administration (FDA) to initiate the pivotal DETOUR II clinical trial. As the first-ever pivotal trial for percutaneous femoropopliteal bypass, DETOUR II will evaluate the safety and effectiveness of the DETOUR System in up to 292 patients with lower limb ischaemia due to long blockages (>15cm) in the superficial femoral artery (SFA) caused by peripheral artery disease (PAD).
BTG today announces it has acquired Roxwood Medical, an innovative provider of advanced cardiovascular specialty catheters used in the treatment of patients with severe coronary and peripheral artery disease.
Boston Scientific has announced the three-year results from the MAJESTIC trial for the Eluvia paclitaxel-eluting vascular stent system at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE), in Copenhagen, Denmark.
The six-month results from the full clinical cohort of the EffPAC randomised study were presented in the drug-coated balloon (DCB) abstracts session at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2017 conference in Copenhagen, Denmark. The data demonstrate the efficacy of iVascular’s Luminor DCB in patients with peripheral arterial disease (PAD).
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos